Recurrent Prolapse After Native-Tissue Repair With Borderline Compartment Involvement

The key insight is that the durability gap between native tissue and mesh-augmented apical repair is largest in exactly this profile: recurrent prolapse, elevated BMI, chronic cough, and constipation. None of these is a contraindication, but together they argue against a second native-tissue suspension with a comparable failure profile.

• Nonmodifiable/less modifiable: prior failed repair, parity with forceps, age, and the chronic cough. The cough raises chronic Valsalva loading; if asthma is truly well controlled, optimize inhaler therapy and consider pulmonary input before elective surgery.
• Modifiable: BMI 31 and constipation. Even modest weight loss and a structured bowel regimen (fiber plus osmotic agent, pelvic floor physical therapy for defecatory behavior) reduce strain. These should be addressed preoperatively but are not reasons to defer indefinitely.
• Obliterative option (colpocleisis): highly durable and low morbidity, but this patient is sexually active? Not stated - must be asked. If she is not sexually active and accepts loss of vaginal capacity, LeFort colpocleisis with perineorrhaphy is the most durable option by many measures and is reasonable given her comorbidity profile. If she wishes to retain coital function, this is off the table.
• Sacrocolpopexy: best supported durability for recurrent apical prolapse in a woman who wants vaginal function. Type I macroporous polypropylene, lightweight, with anterior and posterior arms. Consider concomitant anti-incontinence procedure given stress-predominant leakage.

Given she wants 'the most durable option' and has recurrent disease, I would counsel toward sacrocolpopexy if she desires coital function, or colpocleisis if not, rather than a second native-tissue repair. I would not offer transvaginal mesh kits for primary recurrent apical prolapse given the FDA safety communications and better alternatives.

This is the classic 'occult stress incontinence' decision. She has overt stress-predominant mixed incontinence (4 stress leaks/week), not occult leakage, so the question is not whether to treat but how.

• Cochrane/randomized evidence (CARE trial and related): In women with occult stress incontinence undergoing prolapse surgery, prophylactic midurethral sling reduces postoperative stress incontinence but increases adverse events (UTI, bladder perforation, retention). The number needed to treat is modest; the number needed to harm is also real. Her case is stronger than occult because she has symptomatic stress leakage.
• Urodynamic context: MUCP 38 cm H2O and VLPP 70 cm H2O suggest urethral hypomobility/possible intrinsic sphincter deficiency contribution. A retropubic (TVT) approach has somewhat better evidence in low-pressure urethra than transobturator, though the difference is debated. Either is reasonable; I would lean retropubic given the low VLPP.
• Timing: Performing the sling at the time of sacrocolpopexy addresses the stress component and avoids a second anesthetic; the trade-off is added risk of retention and mesh complications. Some would defer and reassess because apical correction can unmask or resolve symptoms unpredictably. Given overt stress leakage, I would counsel for concomitant retropubic sling rather than a staged approach, while explicitly discussing mesh risk and the possibility of needing a second procedure.

I would not perform a Burch; the evidence favors sling in this population, and Burch adds morbidity without clear benefit.

Isolated recurrent anterior prolapse with a durable apex suggests the failure is at the anterior compartment - either inadequate anterior dissection/attachment at the original sacrocolpopexy or progression of native anterior wall weakness - not failure of the apical suspension. The apex is the anchor; if it holds, the problem is distal.

Options:

1. Observation if asymptomatic or minimally bothersome; anterior wall recurrences are common and not all require surgery.
2. Pessary trial, especially given her comorbidity profile.
3. Anterior colporrhaphy with or without graft if symptomatic and she wants surgical correction. Native-tissue anterior repair has meaningful recurrence rates; biologic or synthetic augmentation has not consistently improved outcomes in randomized trials and adds risk.
4. Revision/extension of the sacrocolpopexy with additional anterior mesh if the anterior arm appears detached or shortened - this requires reoperation and is more morbid.

I would assess whether the anterior mesh arm is still attached and whether the recurrence is symptomatic. If she is symptomatic and desires surgery, a targeted anterior repair (native tissue) is reasonable; I would not place a second synthetic mesh in the anterior compartment without a clear indication given exposure and erosion risk. This case also illustrates that 'durable' apical repair does not guarantee anterior durability.